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BACKGROUND. The authors evaluated the combination of oral cyclophosphamide,
oral prednisone, and diethylstilbestrol (DES) in patients with androgen-indepen-
dent prostate carcinoma (AIPC).
METHODS. Thirty-seven patients with prostate carcinoma refractory to androgen
ablation who had undergone antiandrogen withdrawal (if previously treated with
an antiandrogen) were enrolled in the current study. They were treated with oral
cyclophosphamide 100 mg per day on Days 1–20, prednisone 10 mg per day
continuously, and DES 1 mg continuously, on a 30-day cycle. Warfarin 1 mg per
day was given as prophylaxis for thrombosis. Patient levels of prostate-specific
antigen (PSA) were monitored on a monthly basis, with imaging studies every 3
months. Patients continued to receive therapy until disease progression or the
occurrence of significant toxicity. The effect of therapy on the patient’s quality of
life was assessed using the Functional Assessment of Cancer Therapy–Prostate.
RESULTS. Thirty-six patients were evaluable for response. Of the 36 patients, 15
(42%) had a 50% or greater decline in PSA levels from pretreatment levels and 1
patient (6%) with measurable disease had a partial response to therapy. The
median duration of response was 4.5 months (range, 4 –18 months). The overall
median survival period was 16.4 months. The treatment was well tolerated, with
only three patients removed from the study for toxicities associated with treatment.
One patient, who had been treated for more than 24 months, developed acute
leukemia. Quality of life evaluation in 17 patients showed a significant improve-
ment in responders, whereas nonresponders had no deterioration while receiving
therapy.
CONCLUSIONS. Cyclophosphamide, prednisone, and DES represent a well toler-
ated, low-cost combination therapy with significant activity in the treatment of
patients with AIPC. Cancer 2003;98:1603–10. © 2003 American Cancer Society.
KEYWORDS: androgen-independent prostate carcinoma cyclophosphamide, pred-
nisone, diethylstilbestrol.
Androgen-independent prostate carcinoma (AIPC) remains an in-curable disease. Although AIPC previously was considered to be
chemotherapy-resistant, new drugs and combinations have shown
promise in the treatment of this disease.1 However, more aggressive
treatment can be associated with a higher incidence of treatment-
related morbidity, which often is tolerated poorly in older patients.
Therefore, lower-toxicity combinations are needed.
Diethylstilbestrol (DES) is an estrogen that has been used exten-
sively in the treatment of hormone-dependent prostate carcinoma. In
addition to its estrogenic properties, DES may have direct cytotoxic
effects, which are potentially estrogen receptor–independent.2 Multi-
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ple reports have demonstrated the efficacy of DES as a
first-line hormonal agent. The overall survival of pa-
tients treated with DES was similar to that seen with
orchiectomy3–5 and lutenizing hormone-releasing
hormone (LHRH) agonists.6 –9 However, treatment-re-
lated mortality due to significant cardiovascular tox-
icity led most practitioners to abandon the drug. In
these trials, DES was administered at 3–5 mg orally per
day, as this was the dose considered to reliably provide
castrate levels of testosterone.10,11 Other studies dem-
onstrated that DES at 1 mg daily provided equal effi-
cacy with fewer thromboembolic events.12,13
The low cost of DES and the ease of oral admin-
istration prompted its reevaluation as a secondary
hormonal agent. Smith et al.14 conducted a Phase II
trial using 1 mg DES daily in patients with AIPC. The
response rate was 43% using prostate-specific antigen
(PSA) criteria (defined as a decrease in 2 successive
measurements of PSA of greater than 50% from base-
line). Only 5% of patients had thromboembolic com-
plications. Another trial involving DES at 1 mg per day
in combination with hydrocortisone (40 mg per day)
and low-dose aspirin (75 mg per day) demonstrated a
PSA response rate of 38%.15 In that study, 83% of
symptomatic patients experienced a significant im-
provement in quality of life.
Cyclophosphamide was among the first chemo-
therapeutic agents to be tested in patients with AIPC.
Intravenous cyclophosphamide showed modest effi-
cacy, with response rates in the 10 –20% range as a
single agent16 and in the 30 –50% range in combina-
tion therapy with doxorubicin.17,18 Cyclophospha-
mide, methotrexate, and 5-fluorouracil;19 –21 cyclo-
phosphamide, doxorubicin, and methotrexate;22
cyclophosphamide, cisplatin, and 5-fluorouracil;23
and 5-fluorouracil, doxorubicin, and mitomycin C24
did not show significant improvements in overall sur-
vival or response rates compared with cyclophospha-
mide alone.
Cyclophosphamide is well absorbed when given
orally, with good bioavailability, resulting in levels
comparable to those seen after intravenous adminis-
tration.25 Oral therapy has the added advantages of
decreased toxicity and ease of administration. Initial
results with oral cyclophosphamide in prostate carci-
noma were disappointing when the drug was used in
schedules designed to simulate bolus intravenous
therapy.21 However, when given on a low-dose, inter-
mittent schedule, oral cyclophosphamide produced
more promising results, with PSA response rates of
30 –35%.26 Improvements in performance status and
pain control also were noted.27,28
Prednisone as a single agent also has shown effi-
cacy in the treatment of AIPC. In a Phase III study
comparing mitoxantrone and prednisone with pred-
nisone alone, the primary endpoint of palliative re-
sponse was seen in 21% of patients treated with pred-
nisone alone.29 In a second Phase III trial comparing
flutamide with prednisone, prednisone therapy was
associated with a subjective response rate of 56% and
a PSA response rate of 21%, both of which were similar
to the results achieved with flutamide treatment.30 No
differences were seen between the two treatments in
time to progression or overall survival.
Given the efficacy of these agents, along with the
relatively low and nonoverlapping toxicities, we ex-
plored the activity of oral cyclophosphamide, pred-
nisone, and estrogen in the Dunning rat adenocarci-
noma model. Animals were divided into seven groups
and treated with different combinations of the three
drugs. The group treated with the oral three-agent
regimen had significantly smaller tumors compared
with the other six groups (Fig. 1).
Based on these clinical and laboratory data, we
designed a Phase II trial using the combination of oral
cyclophosphamide, prednisone, and DES (CPD) in the
treatment of AIPC. Because this combination included
well-established drugs with nonoverlapping toxicities,
we did not believe it was necessary to conduct a Phase
I trial before proceeding with the current study, which
FIGURE 1. Animals were implanted with 200,000 MAT-Ly Lu cells. 10
animals per group, on Day 0 and sacrificed on Day 14. Oral drug treatments
started on Day 1. Tumors were excised and weighed on Day 14. Group 1 (P)
was treated with oral prednisone 0.3 mg daily (gavage). Group 2 (E) was treated
orally with esterified estrogens 0.03 mg daily. Group 3 (P  E) was treated
orally with steroid and estrogen. Group 4 (C) was treated with oral cyclophos-
phamide 3 mg per day. Group 5 (C  P  E) was treated with oral
cyclophosphamide, steroid, and estrogen daily Group 6 (Civ) was treated with
30 mg intravenous cyclophosphamide on Days 4 and 11. Group 7 (Civ, P,E) was
treated with intravenous cyclophosphamide on Days 4 and 11 and treated
orally with steroid and estrogen daily. Group 8 (control) consisted of untreated
control animals. The group treated with a combination of oral cyclophospha-
mide, steroid, and estrogen demonstrated a significant decrease in tumor
weight compared with control (P  0.001).
1604 CANCER October 15, 2003 / Volume 98 / Number 8
was designed to assess both the efficacy and impact




Cyclophosphamide was obtained from Sigma (St.
Louis, MO). Esterified estrogens and prednisone were
obtained from the outpatient pharmacy of the Univer-
sity of Michigan (Ann Arbor, MI). All were prepared as
sterile stock solutions of 1 mg/mL normal saline and
stored at 4 °C.
Cell culture
The metastatic MAT-LyLu (MLL) subline of the Dun-
ning R-3327 rat prostate adenocarcinoma line was
obtained from Dr. John Isaacs (Johns Hopkins Univer-
sity, Baltimore, MD). MLL cells were grown and main-
tained in RPMI 1640 (Sigma-Aldrich, St. Louis, MO)
medium containing 10% fetal bovine serum and 250
nM dexamethasone.
Animals
Male Copenhagen rats (200 g) were obtained from
Harlan Sprague-Dawley (Indianapolis, IN). Methoxy-
flurane (Pittman-Moore, Washington Crossing, NJ)
was used as inhalation anesthetic for injections and
surgical procedures that were performed according to
approved University of Michigan protocols.
Experimental treatment
Animals, 10 per group, were injected with 1  106 MLL
cells subcutaneously into the flank on Day 0, based on
a protocol approved by the University of Michigan
Animal Investigation Committee. Animals were im-
planted with 1  106 MLL cells, 10 animals per group,
on Day 0 and killed on Day 14. Oral drug treatments
started on Day 1. Tumors were excised and weighed
on Day 14. Group 1 was treated with oral prednisone
0.3 mg daily (gavage). Group 2 was treated orally with
estrogen in the form of Estratabs 0.03 mg daily. Group
3 was treated orally with steroid and estrogen. Group
4 was treated orally with cyclophosphamide 3 mg per
day. Group 5 was treated orally with cyclophospha-
mide, steroid, and estrogen every day. Group 6 was
treated with 30 mg intravenous cyclophosphamide on
Days 4 and 11. Group 7 was treated with intravenous
cyclophosphamide on Days 4 and 11 and with oral
steroid and estrogen daily. Group 8 consisted of un-
treated control animals. Tumor size was followed by
caliper measurements along two axes and by final
tumor weight when animals were killed by carbon
dioxide inhalation euthanasia on Day 14.
Statistics
Statistical significance was determined using the Stu-
dent t test as well as analysis of variance with Stat-
graphics software (Version 5.0; STSC, Rockville, MD).
Patients
Eligible patients were required to have a histologic
diagnosis of adenocarcinoma of the prostate with pro-
gressive disease on hormone therapy. All patients who
had not undergone orchiectomy underwent primary
androgen suppression using an LHRH agonist. All pa-
tients receiving antiandrogen therapy at the time of
progression underwent antiandrogen withdrawal,
with evidence of disease progression after cessation of
the antiandrogen. Patients were required to have a
performance status of 2 or better on the Zubrod scale,
along with a life expectancy of 12 weeks or more and
adequate bone marrow (absolute neutrophil count
 1500/mm3 and platelet count of  100,000/mm3),
renal (creatinine level  1.3 mg/dL), and hepatic func-
tion (bilirubin level  1.6 mg/dL and an aspartate
aminotransferase level  3 times the upper limit of
normal). Patients were required to have either mea-
surable soft tissue disease or evaluable disease (osse-
ous disease with increasing levels of PSA or increasing
levels of PSA alone). Patients were excluded from the
study if there was evidence of brain metastases or
spinal cord compression, untreated second malignan-
cies, recent myocardial infarction, unstable angina,
uncontrolled arrhythmia, valvular heart disease with
decreased ejection fraction, uncontrolled hyperten-
sion, or history of deep venous thrombosis (DVT). To
enter the study, patients were required to wait 4 weeks
after the completion of any prior chemotherapy, bio-
logic therapy, or radiotherapy. Written, informed con-
sent was obtained from all patients in accordance with
federal, state, and institutional guidelines.
Evaluations
Pretreatment evaluations consisted of a history and
physical examination, complete blood count, serum
chemistry profile, and PSA level measurement. Base-
line imaging included a chest X-ray, a bone scan, and
a computed tomography (CT) scan of the abdomen
and pelvis. Complete blood counts and PSA levels
were checked before each cycle of therapy. CT and
bone scans, if positive at baseline, were repeated after
every 3 cycles of therapy (90 days).
Quality of Life Evaluations
The Functional Assessment of Cancer Therapy–Pros-
tate (FACT-P) was developed as a disease-specific
quality of life instrument for patients with prostate
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carcinoma. The general FACT is a 33-item instrument
that measures quality of life using five subscales ad-
dressing physical well-being, social/family well-being,
relationship with physician, emotional well-being,
and functional well-being.31 The general FACT has
demonstrated validity and reliability. The FACT-P sub-
scale provides an additional 12 items that are specific
to quality of life issues in men with prostate carci-
noma, including sexuality, elimination, and comfort.
The FACT-P was administered at baseline and
monthly during therapy. Study participants com-
pleted the questionnaire before being evaluated by the
clinical staff at each visit.
Treatment Regimen
All evaluations were performed in the outpatient
clinic, and the medication was self-administered.
Treatment consisted of cyclophosphamide adminis-
tered daily at a dose of 100 mg orally on Days 1–20 of
every 30-day cycle, prednisone 10 mg orally every day
continuously, and DES 1 mg orally every day contin-
uously. In addition, warfarin 1 mg orally every day also
was given continuously to decrease the risk of DVT.
Dose modification for cyclophosphamide was based
on granulocyte and platelet counts from Day 21 of the
preceding cycle. If anemia or thrombocytopenia de-
veloped, cyclophosphamide was held until the granu-
locyte count was 1500/mm3 or greater and the platelet
count was 100,000/mm3 or greater. If the granulocyte
count was less than 1000/mm3 or the platelet count
was less than 50,000/mm3, all therapy was held until
the toxicity resolved. When the bone marrow had re-
covered adequately, the dose of cyclophosphamide
was decreased by 50% (to 50 mg per day) if the Day 21
granulocyte count was 1000 –1499/mm3 and/or the
Day 21 platelet count was 50,000 –74,999/mm3. Ther-
apy also was held for any toxicity worse than Grade 2
according to the National Cancer Institute Common
Toxicity criteria. When the toxicity resolved to Grade
 2, cyclophosphamide was resumed at a dose of 50
mg per day. Subsequent cycles were given at full dose
if there was no recurrence of toxicity. Patients were
eligible to receive therapy indefinitely unless they had
evidence of disease progression or a qualitatively un-
acceptable or life-threatening toxicity, were unable to
comply with protocol requirements, or requested to
stop receiving therapy.
Response Criteria
Response was assessed using standard criteria for
measurable disease, if present. Complete response of
bone-only disease required the disappearance of all
measurable and evaluable lesions, with a decrease in
serum levels of PSA to less than 0.1 ng/mL for at least
4 weeks. A partial response for measurable lesions was
defined as a decrease below baseline of 50% or greater
in the sum of the products of the perpendicular diam-
eters of all measurable lesions. A partial response for
PSA was defined as a 50% -or- greater decrease, lasting
at least 4 weeks, from a given patient’s baseline PSA
level. Disease progression was defined as a 50% in-
crease in PSA levels from nadir levels, a 25% increase
or an increase of 10 cm2 in the sum of the products of
measurable lesion diameters, the appearance of any
lesion that had disappeared or any new lesion, clear
worsening of evaluable disease, or significantly in-
creasing symptoms secondary to disease progression.
All patients who did not meet these criteria were con-
sidered to have stable disease.
Statistical Considerations
The current study was designed to assess the efficacy
of CPD, with a primary end point of tumor response.
Response was assessed using serum PSA levels and
measurable disease, if present. A Minimax two-stage
accrual design provided 80% statistical power at the
5% significance level to assess the difference between
the null response rate of 20% and the alternative re-
sponse rate of 40%. The aim of the study was to
determine whether the three-drug combination had a
response rate similar to that of DES alone or that of the
two-drug combination of cyclophosphamide and
prednisone (both response rates were approximately
40% in Phase II trials). As such, the combination
would not have been of further interest unless the
response rate was at least that of its components.
Kaplan–Meier methods were used to determine me-
dian survival times. The Student t test was used to




Between September 1998 and July 2001, 37 patients
were enrolled in the current study. Patient character-
istics are listed in Table 1. One patient was ineligible
for the study secondary to evidence of chronic lym-
phocytic leukemia after entry laboratory studies were
performed. This patient continued to receive the reg-
imen and was followed for toxicity.
Of the remaining 36 patients, 15 previously had
received treatment with chemotherapy. Three patients
had received more than one regimen. The most com-
mon previous therapy was a combination of uracil
with tegafur and leucovorin (n  5), which was a
previous study regimen at The University of Michigan
Comprehensive Cancer Center. Other regimens in-
cluded single-agent estramustine (n  2), estramus-
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tine/etoposide (n  3), cyclophosphamide/pred-
nisone (n  1), paclitaxel/estramustine/etoposide/
cisplatin (n  2), mitoxantrone/prednisone (n  2),
paclitaxel/estramustine/etoposide (n  3), and vaccine
therapy (n  1). Sixteen patients had evidence of soft
tissue disease before starting treatment, 27 had evidence
of bone disease, 10 had both bone and soft tissue dis-
ease, and 4 had elevated PSA levels only.
Response
Thirty-six patients were assessable for response. Of
the 36 patients, 15 (42%) had a greater-than-50% de-
cline in PSA levels while receiving therapy, with 7
patients (19%) having a greater-than-75% decline. The
median duration of response in patients with a greater-
than-50% reduction in PSA level was 9 months. The
median overall survival was 16.4 months.
Of the 15 patients with an initial PSA response, 3
were removed from the study due to disease progres-
sion as evidenced by a bone scan, 1 patient due to new
measurable lesions as shown on CT scan, 3 patients
due to PSA progression, and 5 patients due to toxicity
or intolerance (1 thromboembolic event, 1 episode of
urosepsis, 1 case of worsening lower-extremity edema,
1 case of breast tenderness, and 1 case of inability to
travel to appointments). Three patients remained in
the study without definable progression, 1 for 15
months and 2 for 18 months. Due to concerns about
bladder and bone marrow toxicity, cyclophosphamide
and prednisone were discontinued and these patients
were maintained on DES alone.
Response was assessed by standard criteria in the
16 patients with bidimensional measurable disease.
One patient had evidence of a partial response, and
one patient demonstrated stable disease. Both pa-
tients had a PSA response, and neither had received
previous chemotherapy.
Previous chemotherapy may have influenced re-
sponse. For example, 4 of 15 patients (26%) who had
received previous chemotherapy had a greater-than-
50% decline in PSA levels, compared with 11 of 21
(52%) patients who had not received previous therapy.
However, the pretreatment PSA level did not affect
response, and nor did the presence or absence of
lesions as demonstrated on CT or bone scan. Original
Gleason score also did not appear to affect response,
as PSA responses were seen in 3 of 9 (33%) patients
with a score of 2– 6, 4 of 9 (44%) patients with a score
of 7, and 8 of 17 (47%) patients with a score of 8 –10.
The PSA response could be gradual, with time of max-
imal decrease in PSA levels ranging from 1 to 13
months. The median time to response was 2 cycles.
Toxicity
Two hundred cycles of therapy were delivered (range,
1–18 cycles). Toxicity is summarized in Table 2. Lym-
phopenia was the most common toxicity. Seventeen
patients experienced Grade 3 lymphopenia, and 10
patients experienced Grade 4 decreases in lymphocyte
counts. There were no episodes of Grade 3 or 4 gran-
ulocytopenia, thrombocytopenia, or anemia. Two pa-
tients developed spinal cord compression, one imme-
diately after leaving the study secondary to an
increasing PSA level and one during therapy. Four
patients experienced cardiovascular toxicity, includ-
ing myocardial infarction, (n  1) popliteal DVT (n
 1), a clot in a previously placed abdominal aortic
aneurysm graft (n  1), and paroxysmal atrial fibrilla-
tion (n  1). Other toxicities included a ureteral ob-
struction secondary to disease progression (n  1) and
an episode of urosepsis(n  1). No patients required
dose reduction for any reason while they were en-





Median (range) 66 (51–76)
Initial gleason score
Median (range) 7 (5–9)
PSA at start of treatment
Median (range) 63 (1.1–2021)
Disease status
PSA only 4
Positive bone scan 17
Positive CT scan 6
Positive bone scan and CT scan 10
Previous treatment with chemotherapy
(range of no. of regimens) 15 (0–2)
PSA: prostate-specific antigen; CT: computed tomography.
TABLE 2
Toxicity Data









3 (1 popliteal DVT, 1 clot in AAA graft,
1 episode of atrial fibrillation) 1 (MI)
GI: gastrointestinal; DVT: deep venous thrombosis; AAA: abdominal aortic aneurysm MI: myocardial
infarction.
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Four patients were removed from the study for
reasons other than defined toxicity criteria. One pa-
tient experienced worsening lower extremity edema of
unknown cause but believed to be exacerbated by
prednisone. A second patient had severe breast ten-
derness, a third had a severe increase in bone pain,
and a fourth could not commit to the monthly clinic
appointments called for by the protocol.
Study treatment was halted after 18 months for 3
patients who were still responding to therapy due to
concern for the effects of long-term administration of
cyclophosphamide. One of these patients was main-
tained on DES but experienced a prompt increase in
his PSA level after a 6-month interval. He was restarted
on the 3-drug combination but developed pancyc-
topenia after 6 additional months of therapy. A bone
marrow biopsy revealed blasts consistent with acute
promyelocytic leukemia, which was confirmed by cy-
togenetics. At the time of the current report, this pa-
tient is undergoing induction chemotherapy.
Quality of Life
Seventeen patients were evaluable for quality of life
assessment, including nine patients who responded to
treatment and eight nonresponders. Baseline FACT-P
scores were 120 and 122.6 for nonresponders and re-
sponders, respectively. There was a significant im-
provement in the scores of the group of patients re-
sponding to treatment between the baseline and first
time point. Data were available at these time points
for all nine responding patients. Mean FACT-P scores
were 122.6 at baseline and 133 after the first time point
(P  0.03). Progressive disease was associated with a
decline in quality of life scores. Data were available for
eight patients at the off-treatment time point. The
difference between mean FACT-P scores from Time
Point 2 to the off-treatment time point was significant
(from 133 to 126, P  0.05). Finally, there was no
significant difference between baseline and off-treat-
ment FACT-P results for either responders or nonre-
sponders, suggesting that the treatment itself did not
result in a decline in the quality of life in either group.
DISCUSSION
Many recent trials have shown that chemotherapy for
AIPC has significant efficacy in terms of PSA and even
measurable disease response.1,32 However, because
no overall survival benefit has been demonstrated in a
Phase III trial, the need for more effective and less
toxic therapy remains. All three components of this
combination have demonstrated responses as single
agents in the setting of AIPC. The current study dem-
onstrates that the CPD combination also has signifi-
cant activity, with sustained PSA responses. The low
incidence of side effects makes this an attractive com-
bination for multiple clinical situations, ranging from
the patient with a performance status of 100% who
would like to avoid significant side effects to the pa-
tient with an impaired status who will not tolerate a
more toxic regimen. Nonetheless, cardiovascular tox-
icity was documented in four patients, despite pro-
phylactic low-dose warfarin administration. Quality of
life evaluation during therapy showed no significant
negative effects from this combination even in the
absence of response, whereas responders had a signif-
icant improvement in quality of life scores while they
were receiving therapy.
Despite the favorable toxicity profile, long-term
administration of CPD probably is not a feasible op-
tion. As with all alkylating agents, cyclophosphamide
may cause significant side effects even when given at
low doses. Development of acute promyelocytic leu-
kemia after administration of chemotherapy agents
has been reported.33 This risk appears to be directly
related to the cumulative exposure to cyclophospha-
mide. The patient in the current study who developed
acute leukemia after 24 months of therapy is typical of
patients who develop this second malignancy. The risk
of this complication must be weighed against the po-
tential benefit when considering the use of CPD.
The PSA response rate associated with CPD is
higher than that associated with cyclophosphamide or
prednisone alone, but is similar to that associated with
DES alone.13,14 It is unclear whether the response as-
sociated with the combination can be attributed solely
to DES. In a previously published Phase II trial of DES
as a single agent,14 71% of patients were asymptom-
atic, with a median PSA level of 23.4. None of the
patients in that study had been treated with chemo-
therapy, suggesting that they may have had less-ad-
vanced disease.
Response to CPD typically was of short duration,
although a few patients demonstrated prolonged re-
sponses. Some patients were removed from the study
secondary to meeting PSA criteria for progression
even though their disease burden was clearly and sig-
nificantly improved. For example, one patient’s PSA
level was 184.2 at study entry and reached a nadir level
of 2.2, after 7 cycles of therapy. Although his PSA level
was greater than 50% of his nadir level (i.e.,  3.3) in
the subsequent cycle, the greater than 90% reduction
in his PSA level and the lack of measurable disease
demonstrate the potential impact of this combination.
A practical approach in future trials would be a
randomization of patients to receive DES versus CPD.
Sequential therapy with DES followed by cyclophos-
phamide and prednisone or CPD at the time of pro-
gression also may allow for a longer duration of re-
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sponse with continued minimal toxicity. In clinical
practice, this regimen may be an option for patients
with symptomatic disease, although the current trial
did not attempt to evaluate the impact of therapy on
symptoms, including bone pain. Another option for
future trials would be to assess the impact of CPD as
maintenance therapy after response to one of the an-
timicrotubule regimens that are gaining popularity.
Any such use, however, should be of short duration
with careful attention to cumulative doses of cyclo-
phosphamide.
In the current study, CPD is associated with a 42%
PSA response rate in a series of patients with AIPC.
CPD therapy generally was well tolerated, even in pa-
tients with marginal performance status. Further eval-
uation of this regimen as a palliative intervention or as
short-term maintenance chemotherapy after response
to more aggressive treatments is warranted.
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